
Johnson & Johnson has submitted an sNDA to the FDA for Caplyta for the treatment of bipolar mania.
This report includes a study on patterns of prodromal psychiatric symptoms that may help identify young persons at increased risk of bipolar disorder; sibling bullying and risk of psychotic disorders; and a new smartphone app that tracks moods and predicts bipolar disorder episodes.

